celgene corp (CELG:NASDAQ GS)
James J. Loughlin CPA
Independent Director, Chairman of Audit Committee and Member of Management Compensation & Development Committee, Celgene Corporation
|Age||Total Calculated Compensation||This person is connected to 23 board members in 2 different organizations across 4 different industries.|
See Board Relationships
Mr. James J. Loughlin, C.P.A. was Global Lead Partner in KPMG LLP, Short Hills, New Jersey from 1995 to September 2003. Mr. Loughlin has gained extensive experience serving multinational pharmaceutical manufacturing and distribution companies. He has an extensive background in accounting and financial reporting. He served in various executive positions throughout KPMG, including Managing Partner of Milwaukee, Wisconsin office, Partner-in-Charge of Human Resources for ...
86 Morris AvenuePhone: 908-673-9000
Summit, New Jersey 07901
Board Members Memberships*
Former Director, Chairman of the Audit Committee and Member of the Compensation Committee
Former Director, Chairman of Audit Committee and Member of Corporate Governance & Nominating Committee
Independent Director, Chairman of Audit Committee and Member of Management Compensation & Development Committee
Director and Chairman of Audit Committee
Saint Peter's University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Lamberto Andreotti||Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee|
Bristol-Myers Squibb Company
|George A. Scangos Ph.D.||Chief Executive Officer and Director|
Biogen Idec Inc.
|Leonard S. Schleifer M.D., Ph.D.||Co-Founder, Chief Executive Officer, President, Executive Director and Ex Officio Member of Technology Committee|
Regeneron Pharmaceuticals, Inc.
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Flemming Ornskov M.D., MBA, MPH||Managing Director, Chief Executive Officer and Director|
|$2.7M||Compensation as of Fiscal Year 2013.|